Silo Pharma
SILO
Market cap $5.38M

1.20 USD

+0.03

2.56%

At close Oct 17, 4:00 PM EDT

1 day

2.56%

5 days

17.65%

1 month

10.09%

3 months

-46.67%

6 months

-38.78%

Year to date

-21.05%

1 year

-14.29%

5 years

-76.47%

About: SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

Employees: 3

Consumer Staples Apparel & Other Finished Products Made From Fabrics & Similar Materials

0

Funds holding %

of 6,740 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

0% more funds holding

Funds holding: 10 [Q1] → 10 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.73% less ownership

Funds ownership: 3.97% [Q1] → 3.24% (-0.73%) [Q2]

90% less capital invested

Capital invested by funds: $1.22M [Q1] → $118K (-$1.1M) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for SILO.

See Analyst Rankings

Financial journalist opinion

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Proposal submitted for FDA 505(b)(2) regulatory pathway for SPC-15 approval Advancing path to IND submission for first-in-human trials SARASOTA, FL, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding the Company's development plan for SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD) and stress-induced anxiety disorder.

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company's SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. In addition, Sever Pharma Solutions will continue with analytical testing of the ketamine hydrochloride (ketamine HCL) polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for continuing pre-clinical studies.

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo to advance homing peptide development for initial indication in multiple sclerosis SARASOTA, FL, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into an agreement with WuXi AppTec (Hong Kong) Limited, a leading global contract research organization (CRO), for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS). Silo Pharma is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMB).

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Presentation to feature Silo's novel therapeutics for the underserved SARASOTA, FL, July 26, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that CEO Eric Weisblum will present at the H.C. Wainwright 25th Annual Global Investment Conference to be held September 9-11, 2024.

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, July 22, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that are immediately exercisable upon issuance and will expire five years following the date of issuance.

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

SARASOTA, FL, July 19, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced that it has entered into definitive agreements for the purchase and sale of 763,638 shares of common stock at a purchase price of $2.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 763,638 shares of common stock at an exercise price of $2.75 per share that will be immediately exercisable upon issuance and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about July 22, 2024, subject to the satisfaction of customary closing conditions.

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Why Is Silo Pharma (SILO) Stock Up 60% Today?

Developmental-stage pharmaceutical firm Silo Pharma (NASDAQ: SILO ) — which specializes in both traditional and psychedelic therapeutics to address stress-induced psychiatric disorders — saw its shares rise dramatically on Thursday. Earlier this morning, the company announced a partnership to develop an intranasal drug to address post-traumatic stress disorder (PTSD).

Why Is Silo Pharma (SILO) Stock Up 60% Today?

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Silo Pharma Inc SILO stock is surging on Thursday, with a session volume of 88 million compared to an average volume of 3.2 million, as per data from Benzinga Pro.

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider. Resyca is a joint venture between Bespak Group and Medspray Pharma BV which manufactures the formulation-specific microchip-based spray system chosen by Silo for its lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Silo Pharma Inc SILO shares are trading higher on Tuesday on a high session volume of over 87 million.

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

See News Rankings

Charts implemented using Lightweight Charts™